The Bradford Macula Centre, a part of Bradford Teaching Hospitals NHS Foundation Trust, was officially opened on 20th September 2017, supported by Bayer Pharmaceuticals. This new state-of-the-art centre offers the latest in imaging technology, features the most sophisticated scanning equipment available and is expected to play a leading role in eye health in Bradford. The new Macula Centre is expected to accelerate the patient’s journey through the clinic, and increase the number of patients that can be treated.
The new £500,000 Macula Centre will enable patients with suspected wet macular degeneration to be treated more promptly due to the new fast-track referral system, improving the success of treatment.
A new Optical Coherence Tomography (OCT) scanner for the centre has been funded by Bayer Pharmaceuticals. This latest OCT technology is the most sophisticated equipment available for assessing eye health and detecting conditions such as macular degeneration and diabetic eye disease. A major benefit for patients and ophthalmologists alike, includes the generation of detailed retina images in the absence of dye injections.
O4 Research is significantly involved in ophthalmological late phase studies and is pleased to mark the opening of The Bradford Macula Centre, recognising the significant benefits it will bring to patients with sight-threatening eye conditions.